Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

PNU-99,194

From Wikipedia, the free encyclopedia
Chemical compound
Pharmaceutical compound
PNU-99,194
Clinical data
Routes of
administration
Oral
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
Identifiers
  • 5,6-dimethoxy-N,N-dipropyl-2,3-dihydro-1H-inden-2-amine
CAS Number
PubChemCID
ChemSpider
UNII
ChEMBL
CompTox Dashboard(EPA)
Chemical and physical data
FormulaC17H27NO2
Molar mass277.408 g·mol−1
3D model (JSmol)
  • O(c1cc2c(cc1OC)CC(N(CCC)CCC)C2)C

PNU-99,194(A) (orU-99,194(A)) is adrug of the2-aminoindane family which acts as a moderatelyselectiveD3 receptorantagonist with ~15-30-fold preference for D3 over theD2 subtype.[1][2][3] Though it has substantially greater preference for D3 over D2, the latter receptor does still play some role in its effects, as evidenced by the fact that PNU-99,194 weakly stimulates bothprolactinsecretion andstriataldopaminesynthesis, actions it does not share with the more selective (100-fold) D3 receptor antagonistsS-14,297 andGR-103,691.[4]

Inrodent studies, low doses of PNU-99,194 produceconditioned place preference (CPP) with no effect onintracranial self-stimulation (ICSS), whereas low doses of D3 agonists like7-OH-DPAT inhibit ICSS behavior and causeconditioned place aversion (CPA).[5][6][7] In contrast, high doses of PNU-99,194 produce CPA and inhibit ICSS, while high doses of 7-OH-DPAT result in the opposite.[5][6][7] Paralleling this, low doses of PNU-99,194 and 7-OH-DPAT inducehyperactivity andhypoactivity, respectively, whereas the inverse is seen at high doses with both agents.[2][3][7][8][9][10] These data indicate that the D3 receptor has biphasic effects onreward mechanisms andlocomotor activity, likely due to opposing roles ofautoreceptors versuspostsynapticreceptors.[8][11]

Other effects of PNU-99,194 at low doses in rodents include increasednociceptive responses,[12]hypothermia,[4][13]anxiolysis,[14] and facilitation oflearning andmemory,[12][15][16][17] as well as augmentation and inhibition, respectively, ofamphetamine-induced reward andbehavioral sensitization,[18][19] and reversal ofmorphine-induced CPP.[6] At high doses it inhibits theself-administration of cocaine in both rats and monkeys.[1][20]

See also

[edit]

References

[edit]
  1. ^abClaytor R, Lile JA, Nader MA (March 2006). "The effects of eticlopride and the selective D3-antagonist PNU 99194-A on food- and cocaine-maintained responding in rhesus monkeys".Pharmacology Biochemistry and Behavior.83 (3):456–64.doi:10.1016/j.pbb.2006.03.007.PMID 16631246.S2CID 39482275.
  2. ^abWaters N, Svensson K, Haadsma-Svensson SR, Smith MW, Carlsson A (1993). "The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity".Journal of Neural Transmission. General Section.94 (1):11–9.doi:10.1007/bf01244979.PMID 8129881.S2CID 32918280.
  3. ^abKling-Petersen T, Ljung E, Svensson K (1995). "Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain".Journal of Neural Transmission. General Section.102 (3):209–20.doi:10.1007/bf01281155.PMID 8788069.S2CID 10327706.
  4. ^abAudinot V, Newman-Tancredi A, Gobert A, et al. (October 1998)."A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194".The Journal of Pharmacology and Experimental Therapeutics.287 (1):187–97.PMID 9765337.
  5. ^abKling-Petersen T, Ljung E, Wollter L, Svensson K (1995). "Effects of dopamine D3 preferring compounds on conditioned place preference and intracranial self-stimulation in the rat".Journal of Neural Transmission. General Section.101 (1–3):27–39.doi:10.1007/bf01271543.PMID 8695055.S2CID 30848393.
  6. ^abcFrancès H, Smirnova M, Leriche L, Sokoloff P (September 2004). "Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference".Psychopharmacology.175 (2):127–33.doi:10.1007/s00213-004-1807-9.PMID 15095031.S2CID 2721240.
  7. ^abcKhroyan TV, Baker DA, Neisewander JL (December 1995). "Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning".Psychopharmacology.122 (4):351–7.doi:10.1007/BF02246265.PMID 8657832.S2CID 20542615.
  8. ^abMillan MJ, Seguin L, Gobert A, Cussac D, Brocco M (July 2004). "The role of dopamine D3 compared with D2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats".Psychopharmacology.174 (3):341–57.doi:10.1007/s00213-003-1770-x.PMID 14985929.S2CID 1592299.
  9. ^Gyertyán I, Sághy K (July 2004)."Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011".Behavioural Pharmacology.15 (4):253–62.doi:10.1097/01.fbp.0000137857.26150.ab.PMID 15252275.S2CID 41821358.
  10. ^Rodríguez-Arias M, Felip CM, Broseta I, Miñarro J (May 1999)."The dopamine D3 antagonist U-99194A maleate increases social behaviors of isolation-induced aggressive male mice".Psychopharmacology.144 (1):90–4.doi:10.1007/s002130050981.PMID 10379629.S2CID 20953625. Archived fromthe original on 2000-07-12. Retrieved2010-04-30.
  11. ^Meyer ME (October 1996). "Mesolimbic 7-OH-DPAT affects locomotor activities in rats".Pharmacology Biochemistry and Behavior.55 (2):209–14.doi:10.1016/S0091-3057(96)00066-4.PMID 8951956.S2CID 46728735.
  12. ^abCasarrubea M, Sorbera F, Crescimanno G (November 2006). "Effects of 7-OH-DPAT and U 99194 on the behavioral response to hot plate test, in rats".Physiology & Behavior.89 (4):552–62.doi:10.1016/j.physbeh.2006.07.014.PMID 16919688.S2CID 45464906.
  13. ^Boulay D, Depoortere R, Rostene W, Perrault G, Sanger DJ (April 1999). "Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice".Neuropharmacology.38 (4):555–65.doi:10.1016/S0028-3908(98)00213-5.PMID 10221759.S2CID 1004412.
  14. ^Rogóz Z, Kłodzińska A, Maj J (2000). "Anxiolytic-like effect of nafadotride and PNU 99194A, dopamine D3 receptor antagonists in animal models".Polish Journal of Pharmacology.52 (6):459–62.PMID 11334239.
  15. ^Laszy J, Laszlovszky I, Gyertyán I (May 2005). "Dopamine D3 receptor antagonists improve the learning performance in memory-impaired rats".Psychopharmacology.179 (3):567–75.doi:10.1007/s00213-004-2096-z.PMID 15619116.S2CID 24086632.
  16. ^Hale MW, Crowe SF (July 2002)."The effects of selective dopamine agonists on a passive avoidance learning task in the day-old chick".Behavioural Pharmacology.13 (4):295–301.doi:10.1097/00008877-200207000-00006.PMID 12218510.S2CID 24698131.
  17. ^Hammad H, Wagner JJ (January 2006). "Dopamine-mediated disinhibition in the CA1 region of rat hippocampus via D3 receptor activation".The Journal of Pharmacology and Experimental Therapeutics.316 (1):113–20.doi:10.1124/jpet.105.091579.PMID 16162819.S2CID 10007327.
  18. ^Carr KD, Yamamoto N, Omura M, Cabeza de Vaca S, Krahne L (August 2002). "Effects of the D(3) dopamine receptor antagonist, U99194A, on brain stimulation and d-amphetamine reward, motor activity, and c-fos expression in ad libitum fed and food-restricted rats".Psychopharmacology.163 (1):76–84.doi:10.1007/s00213-002-1132-0.PMID 12185403.S2CID 1840764.
  19. ^Chiang YC, Chen PC, Chen JC (May 2003). "D(3) dopamine receptors are down-regulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine".Brain Research.972 (1–2):159–67.doi:10.1016/S0006-8993(03)02522-8.PMID 12711089.S2CID 40067321.
  20. ^Gál K, Gyertyán I (October 2003). "Targeting the dopamine D3 receptor cannot influence continuous reinforcement cocaine self-administration in rats".Brain Research Bulletin.61 (6):595–601.doi:10.1016/S0361-9230(03)00217-X.PMID 14519456.S2CID 12383682.
Adamantanes
Adenosine antagonists
Alkylamines
Ampakines
Arylcyclohexylamines
Benzazepines
Cathinones
Cholinergics
Convulsants
Eugeroics
Oxazolines
Phenethylamines
Phenylmorpholines
Piperazines
Piperidines
Phenethylpyrrolidines
Racetams
Psychedelics
Tropanes
Tryptamines
Others
D1-like
Agonists
PAMs
Antagonists
D2-like
Agonists
Antagonists
Phenethylamines
Amphetamines
Phentermines
Cathinones
Phenylisobutylamines
(and further-extended)
Catecholamines
(and close relatives)
Cyclized
phenethylamines
Phenylalkylpyrrolidines
2-Benzylpiperidines
(phenidates)
Phenylmorpholines
(phenmetrazines)
Phenyloxazolamines
(aminorexes)
Isoquinolines and
tetrahydroisoquinolines
2-Aminoindanes
2-Aminotetralins
Others / unsorted
Related compounds
Retrieved from "https://en.wikipedia.org/w/index.php?title=PNU-99,194&oldid=1322829527"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp